Incyte (INCY) announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer, CMO, and Head of Late-stage Development. Mohamed Issa, Pharm.D. has been appointed Executive Vice President, EVP, and Head of U.S. Commercial. As part of the transition, Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte Expands Blood Cancer Pipeline With New Early Stage INCA036978 Trial
- Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
- Qualcomm, Adobe downgraded: Wall Street’s top analyst calls
- Incyte downgraded to Hold from Buy at Jefferies
- Incyte Advances New Early Stage Drug INCA033989 Into Human Testing